| Literature DB >> 31815136 |
Abstract
Rhinoconjunctivitis is a public health problem that causes major illness and disability worldwide. Epidemiological studies intended to determine the burden of rhinoconjunctivitis in Kuwait are limited. Hence, this study sought to estimate the prevalence of rhinoconjunctivitis among adolescents in Kuwait and explore its association with different risk factors. Schoolchildren aged 11-14 years (n = 3,864) were enrolled in a cross-sectional study. Parents completed questionnaires regarding their children's clinical history and symptoms of rhinoconjunctivitis and relevant exposures. Associations were assessed using Poisson regression with robust variance estimation, and adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) were estimated. The 12-month (current) prevalence estimates of rhinitis, rhinoconjunctivitis, and severe rhinoconjunctivitis were 28.6% (1,040/3,643), 13.5% (497/3,689), and 1.2% (44/3,689), respectively. The prevalence of current rhinoconjunctivitis symptoms was higher in boys compared to girls (aPR = 1.19, 95% CI: 1.01-1.41). Parental history of rhinitis and asthma showed positive associations with rhinoconjunctivitis in offspring. Trend analyses showed that rhinoconjunctivitis prevalence decreased with increasing numbers of total siblings (aPR = 0.92, P trend < 0.001) and older siblings (aPR = 0.90, P trend < 0.001). Rhinoconjunctivitis is common among adolescents in Kuwait and its epidemiology is similar to that found in western countries.Entities:
Mesh:
Year: 2019 PMID: 31815136 PMCID: PMC6878814 DOI: 10.1155/2019/3981064
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Characteristics of the total study sample and the analytical study sample.
| Variables | Total study sample ( | Analytical study sample ( |
|---|---|---|
|
| ||
| Female | 2169 (56.1) | 2061 (55.9) |
| Male | 1695 (43.9) | 1628 (44.1) |
|
| ||
|
| ||
| Median (5th, 95th percentile) | 12.0 (11.0, 14.0) | 12.0 (11.0, 14.0) |
|
| ||
|
| ||
| Underweight (<−2 SD) | 219 (5.8) | 211 (5.8) |
| Normal (−2 to 1 SD) | 1517 (40.1) | 1450 (40.1) |
| Overweight (>1 to 2 SD) | 961 (25.3) | 916 (25.3) |
| Obese (>2 SD) | 1089 (28.8) | 1039 (28.7) |
| Missing, | 78 | 73 |
|
| ||
|
| ||
| Vaginal | 3106 (81.8) | 2979 (81.6) |
| Cesarean section | 692 (18.2) | 670 (18.4) |
| Missing, | 66 | 40 |
|
| ||
|
| ||
| Yes | 2894 (76.3) | 2777 (76.3) |
| Missing, | 72 | 49 |
|
| ||
|
| ||
| Yes | 232 (6.1) | 227 (6.2) |
| Missing, | 35 | 18 |
|
| ||
|
| ||
| Yes | 500 (13.1) | 479 (13.1) |
| Missing, | 36 | 20 |
|
| ||
|
| ||
| Yes | 85 (2.2) | 82 (2.2) |
| Missing, | 32 | 17 |
|
| ||
|
| ||
| Yes | 119 (3.1) | 113 (3.1) |
| Missing, | 28 | 14 |
|
| ||
|
| ||
| Yes | 1755 (45.8) | 1682 (45.7) |
| Missing, | 28 | 12 |
|
| ||
|
| ||
| Yes | 1736 (46.4) | 1700 (46.8) |
| Missing, | 126 | 59 |
|
| ||
|
| ||
| Yes | 1238 (32.9) | 1207 (33.1) |
| Missing, | 102 | 39 |
|
| ||
|
| ||
| Yes | 904 (24.1) | 880 (24.2) |
| Missing, | 108 | 46 |
BMI: body mass index; SD: standard deviation; ETS: Environmental tobacco smoke. §Sample of participants with complete information regarding rhinoconjunctivitis (i.e., excluding 175 subjects with incomplete information regarding rhinoconjunctivitis). Maternal and/or paternal history of doctor-diagnosed rhinitis. †Maternal and/or paternal history of doctor-diagnosed asthma. ‡Maternal and/or paternal history of doctor-diagnosed eczema.
Prevalence of ever doctor-diagnosed rhinitis and current symptoms of rhinitis, rhinoconjunctivitis, and severe rhinoconjunctivitis in the total analytical sample and stratified by sex.
| % ( | 95% CI | Sex difference | |
|---|---|---|---|
|
| |||
| Total | 25.1 (917/3652) | 23.7–26.5 | |
| Males | 28.4 (459/1614) | 26.2–30.6 | |
| Females | 22.5 (458/2038) | 20.6–24.3 | <0.001 |
|
| |||
|
| |||
| Total | 28.6 (1040/3643) | 27.1–30.0 | |
| Males | 31.6 (509/1611) | 29.3–33.9 | |
| Females | 26.1 (531/2032) | 24.2–28.0 | <0.001 |
|
| |||
|
| |||
| Total | 13.5 (497/3689) | 12.4–14.6 | |
| Males | 15.3 (249/1628) | 13.6–17.0 | |
| Females | 12.0 (248/2061) | 10.6–13.4 | 0.004 |
|
| |||
|
| |||
| Total | 1.2 (44/3689) | 0.8–1.5 | |
| Males | 1.4 (23/1628) | 0.8–2.0 | |
| Females | 1.0 (21/2061) | 0.6–15 | 0.274 |
CI: confidence interval. Comparing prevalence in males and females using chi-squared tests.
Figure 1Monthly and seasonal variations in the prevalence of rhinoconjunctivitis symptoms. The shown prevalence estimates were calculated among individuals reporting rhinoconjunctivitis symptoms in the past 12 months.
Crude and adjusted associations between personal attributes and risk factors and current rhinoconjunctivitis.
| Rhinoconjunctivitis, % ( | Crude PR (95% CI) | Adjusted PR§ (95% CI) | |
|---|---|---|---|
|
| |||
| Female | 12.0 (248/2061) | 1.00 (ref.) | 1.00 (ref.) |
| Male | 15.3 (249/1628) | 1.27 (1.08–1.50) | 1.19 (1.01–1.41) |
|
| |||
|
| |||
| Median (5th, 95th percentile) | — | 1.00 (0.94–1.07) | 1.01 (0.94–1.08) |
|
| |||
| Underweight (<−2 SD) | 10.4 (22/211) | 0.82 (0.54–1.26) | 0.83 (0.55–1.26) |
| Normal (−2 to 1 SD) | 12.6 (183/1450) | 1.00 (ref.) | 1.00 (ref.) |
| Overweight (>1 to 2 SD) | 13.3 (122/916) | 1.06 (0.85–1.31) | 1.08 (0.87–1.33) |
| Obese (>2 SD) | 15.8 (164/1039) | 1.25 (1.03–1.52) | 1.17 (0.96–1.42) |
|
| |||
|
| |||
| Vaginal | 13.0 (387/2979) | 1.00 (ref.) | 1.00 (ref.) |
| Cesarean section | 15.7 (105/670) | 1.21 (0.99–1.47) | 1.09 (0.89–1.33) |
|
| |||
|
| |||
| No | 13.9 (120/863) | 1.00 (ref.) | — |
| Yes | 13.4 (374/2777) | 0.96 (0.79–1.16) | — |
|
| |||
|
| |||
| No | 13.4 (463/3444) | 1.00 (ref.) | — |
| Yes | 14.5 (33/227) | 1.08 (0.78–1.50) | — |
|
| |||
|
| |||
| No | 13.1 (419/3190) | 1.00 (ref.) | 1.00 (ref.) |
| Yes | 15.9 (76/479) | 1.21 (0.97–1.51) | 1.17 (0.93–1.48) |
|
| |||
|
| |||
| No | 13.3 (477/3590) | 1.00 (ref.) | 1.00 (ref.) |
| Yes | 22.0 (18/82) | 1.65 (1.09–2.51) | 1.39 (0.92–2.09) |
|
| |||
|
| |||
| No | 13.4 (477/3562) | 1.00 (ref.) | — |
| Yes | 15.0 (17/113) | 1.12 (0.72–1.76) | — |
|
| |||
|
| |||
| No | 12.5 (249/1995) | 1.00 (ref.) | 1.00 (ref.) |
| Yes | 14.6 (246/1682) | 1.17 (0.99–1.38) | 1.13 (0.95–1.33) |
|
| |||
|
| |||
| No | 6.3 (121/1930) | 1.00 (ref.) | 1.00 (ref.) |
| Yes | 21.7 (368/1700) | 3.45 (2.84–4.20) | 3.14 (2.53–3.90) |
|
| |||
|
| |||
| No | 10.6 (258/2443) | 1.00 (ref.) | 1.00 (ref.) |
| Yes | 19.2 (232/1207) | 1.82 (1.55–2.14) | 1.26 (1.05–1.50) |
|
| |||
|
| |||
| No | 11.9 (328/2763) | 1.00 (ref.) | 1.00 (ref.) |
| Yes | 18.2 (160/880) | 1.53 (1.29–1.82) | 1.09 (0.91–1.31) |
ETS: Environmental tobacco smoke; PR: prevalence ratio; CI: confidence interval; BMI: body mass index; SD: standard deviation; ref.: reference. §Variables that had a p value ≤0.2 in the crude model were simultaneously included in the adjusted (multivariable) model, except for age and sex, which were included in all adjusted model. In addition to the shown variables, “total number of siblings” was included in the multivariable model as it had a p value ≤0.2 in the crude model. Maternal and/or paternal history of doctor-diagnosed rhinitis. †Maternal and/or paternal history of doctor-diagnosed asthma. ‡Maternal and/or paternal history of doctor-diagnosed eczema.
Crude and adjusted associations between the total number of siblings, number of older siblings, and number of younger siblings and current rhinoconjunctivitis.
| Rhinoconjunctivitis, % ( | Crude PR | Adjusted PR† (95% CI) | |
|---|---|---|---|
|
| |||
| 0 | 18.0 (7/39) | 1.00 (ref.) | 1.00 (ref.) |
| 1 | 15.8 (32/202) | 0.88 (0.42–1.86) | 0.84 (0.42–1.69) |
| 2 | 15.8 (60/381) | 0.88 (0.43–1.79) | 0.81 (0.41–1.57) |
| 3 | 16.9 (116/688) | 0.94 (0.47–1.88) | 0.86 (0.45–1.65) |
| ≥4 | 11.9 (277/2330) | 0.66 (0.34–1.31) | 0.62 (0.33–1.18) |
| Per additional sibling | — | 0.91 (0.87–0.95) | 0.92 (0.88–0.96) |
|
| — | <0.001 | <0.001 |
|
| |||
|
| |||
| 0 | 14.4 (152/1055) | 1.00 (ref.) | 1.00 (ref.) |
| 1 | 14.3 (112/784) | 0.96 (0.77–1.21) | 0.93 (0.74–1.16) |
| 2 | 16.5 (101/614) | 1.04 (0.82–1.32) | 0.98 (0.77–1.23) |
| 3 | 11.8 (57/485) | 0.74 (0.55–0.99) | 0.71 (0.53–0.95) |
| ≥4 | 10.0 (74/743) | 0.61 (0.45–0.81) | 0.59 (0.44–0.80) |
| Per additional older sibling | — | 0.90 (0.86–0.95) | 0.90 (0.85–0.94) |
|
| — | <0.001 | <0.001 |
|
| |||
|
| |||
| 0 | 13.1 (69/526) | 1.00 (ref.) | 1.00 (ref.) |
| 1 | 13.9 (102/736) | 0.98 (0.73–1.30) | 0.97 (0.72–1.30) |
| 2 | 14.9 (113/761) | 0.98 (0.73–1.30) | 1.02 (0.76–1.36) |
| 3 | 14.8 (114/770) | 0.92 (0.69–1.23) | 0.94 (0.70–1.27) |
| ≥4 | 11.1 (92/831) | 0.68 (0.50–0.92) | 0.74 (0.54–1.01) |
| Per additional younger sibling | — | 0.93 (0.88–0.98) | 0.94 (0.89–1.00) |
|
| — | 0.008 | 0.050 |
PR: prevalence ratio; CI: confidence interval; ref.: reference. PRs of older siblings were simultaneously adjusted for younger siblings, and PRs of younger siblings were simultaneously adjusted for older siblings. †Adjusted for sex, age, body mass index, mode of birth, current cat exposure, dog exposure in infancy, environmental tobacco smoke exposure, parental history of rhinitis, parental history of asthma, and parental history of eczema. Additionally, PRs of older siblings were simultaneously adjusted for younger siblings, and PRs of younger siblings were simultaneously adjusted for older siblings.
Figure 2Prevalence of severe rhinoconjunctivitis symptoms according to perennial rhinoconjunctivitis symptoms. Participants were considered to have perennial rhinoconjunctivitis if symptoms were reported for more than 9 months in the past 12 months; otherwise, participants were not considered to have perennial rhinoconjunctivitis symptoms.